ID   COMP_HUMAN              Reviewed;         757 AA.
AC   P49747; B4DKJ3; O14592; Q16388; Q16389; Q2NL86; Q8N4T2;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2008, sequence version 2.
DT   18-JUN-2025, entry version 224.
DE   RecName: Full=Cartilage oligomeric matrix protein {ECO:0000305};
DE            Short=COMP;
DE   AltName: Full=Thrombospondin-5;
DE            Short=TSP5;
DE   Flags: Precursor;
GN   Name=COMP {ECO:0000312|HGNC:HGNC:2227};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ASP-50; TRP-51;
RP   GLY-109; GLY-224 AND PRO-285.
RC   TISSUE=Cartilage;
RX   PubMed=7713493; DOI=10.1006/geno.1994.1649;
RA   Newton G., Weremowicz S., Morton C.C., Copeland N.G., Gilbert D.J.,
RA   Jenkins N.A., Lawler J.;
RT   "Characterization of human and mouse cartilage oligomeric matrix protein.";
RL   Genomics 24:435-439(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ASP-50; TRP-51;
RP   GLY-109; GLY-224 AND PRO-285.
RA   Hashimoto Y., Mori H.;
RT   "Human comp cDNA with 5 SNIPs.";
RL   Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 326-344, VARIANT EDM1 TYR-342, AND
RP   VARIANT PSACH ARG-328.
RX   PubMed=7670472; DOI=10.1038/ng0795-330;
RA   Briggs M.D., Hoffman S.M.G., King L.M., Olsen A.S., Mohrenweiser H.,
RA   Leroy J.G., Mortier G.R., Rimoin D.L., Lachman R.S., Gaines E.S.,
RA   Cekleniak J.A., Knowlton R.G., Cohn D.H.;
RT   "Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in
RT   the cartilage oligomeric matrix protein gene.";
RL   Nat. Genet. 10:330-336(1995).
RN   [8]
RP   PROTEIN SEQUENCE OF 80-89, SUBUNIT, CALCIUM-BINDING, AND CHARACTERIZATION
RP   OF VARIANT PSACH ASP-469 DEL.
RX   PubMed=10852928; DOI=10.1074/jbc.m909780199;
RA   Chen H., Deere M., Hecht J.T., Lawler J.;
RT   "Cartilage oligomeric matrix protein is a calcium-binding protein, and a
RT   mutation in its type 3 repeats causes conformational changes.";
RL   J. Biol. Chem. 275:26538-26544(2000).
RN   [9]
RP   PROTEIN SEQUENCE, CALCIUM-BINDING, INTERACTION WITH COLLAGEN I; COLLAGEN II
RP   AND COLLAGEN IX, CHARACTERIZATION OF VARIANT PSACH ASP-469 DEL, AND
RP   CHARACTERIZATION OF VARIANT EDM1 TYR-361.
RX   PubMed=11084047; DOI=10.1074/jbc.m009512200;
RA   Thur J., Rosenberg K., Nitsche D.P., Pihlajamaa T., Ala-Kokko L.,
RA   Heinegaard D., Paulsson M., Maurer P.;
RT   "Mutations in cartilage oligomeric matrix protein causing
RT   pseudoachondroplasia and multiple epiphyseal dysplasia affect binding of
RT   calcium and collagen I, II, and IX.";
RL   J. Biol. Chem. 276:6083-6092(2001).
RN   [10]
RP   INTERACTION WITH FN1.
RX   PubMed=12225811; DOI=10.1016/s0945-053x(02)00015-x;
RA   Di Cesare P.E., Chen F.S., Moergelin M., Carlson C.S., Leslie M.P.,
RA   Perris R., Fang C.;
RT   "Matrix-matrix interaction of cartilage oligomeric matrix protein and
RT   fibronectin.";
RL   Matrix Biol. 21:461-470(2002).
RN   [11]
RP   INTERACTION WITH MATN1; MATN3 AND MATN4.
RX   PubMed=15075323; DOI=10.1074/jbc.m403778200;
RA   Mann H.H., Oezbek S., Engel J., Paulsson M., Wagener R.;
RT   "Interactions between the cartilage oligomeric matrix protein and
RT   matrilins. Implications for matrix assembly and the pathogenesis of
RT   chondrodysplasias.";
RL   J. Biol. Chem. 279:25294-25298(2004).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH ITGB3 AND ITGA5.
RX   PubMed=16051604; DOI=10.1074/jbc.m504778200;
RA   Chen F.-H., Thomas A.O., Hecht J.T., Goldring M.B., Lawler J.;
RT   "Cartilage oligomeric matrix protein/thrombospondin 5 supports chondrocyte
RT   attachment through interaction with integrins.";
RL   J. Biol. Chem. 280:32655-32661(2005).
RN   [13]
RP   FUNCTION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=16542502; DOI=10.1186/ar1922;
RA   Koelling S., Clauditz T.S., Kaste M., Miosge N.;
RT   "Cartilage oligomeric matrix protein is involved in human limb development
RT   and in the pathogenesis of osteoarthritis.";
RL   Arthritis Res. Ther. 8:R56-R56(2006).
RN   [14]
RP   INTERACTION WITH ADAMTS12.
RX   PubMed=16611630; DOI=10.1074/jbc.m513433200;
RA   Liu C.-J., Kong W., Xu K., Luan Y., Ilalov K., Sehgal B., Yu S.,
RA   Howell R.D., Di Cesare P.E.;
RT   "ADAMTS-12 associates with and degrades cartilage oligomeric matrix
RT   protein.";
RL   J. Biol. Chem. 281:15800-15808(2006).
RN   [15]
RP   INTERACTION WITH ACAN; HEPARIN; HEPARAN SULFATE AND CHONDROITIN SULFATE.
RX   PubMed=17588949; DOI=10.1074/jbc.m611390200;
RA   Chen F.-H., Herndon M.E., Patel N., Hecht J.T., Tuan R.S., Lawler J.;
RT   "Interaction of cartilage oligomeric matrix protein/thrombospondin 5 with
RT   aggrecan.";
RL   J. Biol. Chem. 282:24591-24598(2007).
RN   [16]
RP   FUNCTION, AND DOMAINS.
RX   PubMed=17993464; DOI=10.1074/jbc.m704035200;
RA   Gagarina V., Carlberg A.L., Pereira-Mouries L., Hall D.J.;
RT   "Cartilage oligomeric matrix protein protects cells against death by
RT   elevating members of the IAP family of survival proteins.";
RL   J. Biol. Chem. 283:648-659(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   PROTEOLYTIC CLEAVAGE BY ADAMTS4 AND ADAMTS1.
RX   PubMed=39672391; DOI=10.1016/j.matbio.2024.12.005;
RA   de Groot R., Folgado P.B., Yamamoto K., Martin D.R., Koch C.D., Debruin D.,
RA   Blagg S., Minns A.F., Bhutada S., Ahnstroem J., Larkin J., Aspberg A.,
RA   Oennerfjord P., Apte S.S., Santamaria S.;
RT   "Cleavage of Cartilage Oligomeric Matrix Protein (COMP) by ADAMTS4
RT   generates a neoepitope associated with osteoarthritis and other forms of
RT   degenerative joint disease.";
RL   Matrix Biol. 135:106-124(2025).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (3.15 ANGSTROMS) OF 225-757 IN COMPLEX WITH CALCIUM
RP   IONS, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-742.
RX   PubMed=19276170; DOI=10.1096/fj.08-128090;
RA   Tan K., Duquette M., Joachimiak A., Lawler J.;
RT   "The crystal structure of the signature domain of cartilage oligomeric
RT   matrix protein: implications for collagen, glycosaminoglycan and integrin
RT   binding.";
RL   FASEB J. 23:2490-2501(2009).
RN   [20]
RP   VARIANTS PSACH SER-459 DEL; TYR-468 AND TYR-472.
RX   PubMed=7670471; DOI=10.1038/ng0795-325;
RA   Hecht J.T., Nelson L.D., Crowder E., Wang Y., Elder F.F.B., Harrison W.R.,
RA   Francomano C.A., Prange C.K., Lennon G.G., Deere M., Lawler J.;
RT   "Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause
RT   pseudoachondroplasia.";
RL   Nat. Genet. 10:325-329(1995).
RN   [21]
RP   VARIANT EDM1 LYS-523.
RX   PubMed=9021009;
RX   DOI=10.1002/(sici)1096-8628(19970211)68:4<396::aid-ajmg4>3.3.co;2-r;
RA   Ballo R., Briggs M.D., Cohn D.H., Knowlton R.G., Beighton P.H.,
RA   Ramesar R.S.;
RT   "Multiple epiphyseal dysplasia, ribbing type: a novel point mutation in the
RT   COMP gene in a South African family.";
RL   Am. J. Med. Genet. 68:396-400(1997).
RN   [22]
RP   VARIANT EDM1 SER-371, AND VARIANT PSACH 513-VAL--LYS-516 DEL.
RX   PubMed=9184241; DOI=10.1111/j.1399-0004.1997.tb02458.x;
RA   Susic S., McGrory J., Ahier J., Cole W.G.;
RT   "Multiple epiphyseal dysplasia and pseudoachondroplasia due to novel
RT   mutations in the calmodulin-like repeats of cartilage oligomeric matrix
RT   protein.";
RL   Clin. Genet. 51:219-224(1997).
RN   [23]
RP   VARIANTS PSACH, VARIANTS EDM1 SER-453 AND ARG-585, AND VARIANT PSACH
RP   GLU-440.
RX   PubMed=9463320; DOI=10.1086/301713;
RA   Briggs M.D., Mortier G.R., Cole W.G., King L.M., Golik S.S.,
RA   Bonaventure J., Nuytinck L., de Paepe A., Leroy J.G., Biesecker L.,
RA   Lipson M., Wilcox W.R., Lachman R.S., Rimoin D.L., Knowlton R.G.,
RA   Cohn D.H.;
RT   "Diverse mutations in the gene for cartilage oligomeric matrix protein in
RT   the pseudoachondroplasia-multiple epiphyseal dysplasia disease spectrum.";
RL   Am. J. Hum. Genet. 62:311-319(1998).
RN   [24]
RP   VARIANTS PSACH AND EDM1, VARIANTS PSACH ASN-290; VAL-349; GLY-387; GLY-473
RP   AND ASN-518, AND VARIANT EDM1 VAL-361.
RX   PubMed=9921895; DOI=10.1007/s004390050883;
RA   Ikegawa S., Ohashi H., Nishimura G., Kim K.C., Sannohe A., Kimizuka M.,
RA   Fukushima Y., Nagai T., Nakamura Y.;
RT   "Novel and recurrent COMP (cartilage oligomeric matrix protein) mutations
RT   in pseudoachondroplasia and multiple epiphyseal dysplasia.";
RL   Hum. Genet. 103:633-638(1998).
RN   [25]
RP   VARIANTS PSACH ARG-328; ASP-372 DEL; 391-PRO--ASP-394 DELINS VAL; ARG-440;
RP   SER-459 DEL; TYR-468; ASP-469 DEL AND TYR-472, AND VARIANTS EDM1 TYR-342;
RP   TYR-361; 367-ARG-GLY-368 DEL AND TYR-408.
RX   PubMed=9452026; DOI=10.1002/humu.1380110105;
RA   Loughlin J., Irven C., Mustafa Z., Briggs M.D., Carr A., Lynch S.-A.,
RA   Knowlton R.G., Cohn D.H., Sykes B.;
RT   "Identification of five novel mutations in cartilage oligomeric matrix
RT   protein gene in pseudoachondroplasia and multiple epiphyseal dysplasia.";
RL   Hum. Mutat. Suppl. 1:S10-S17(1998).
RN   [26]
RP   VARIANT PSACH GLY-482.
RX   PubMed=9452063; DOI=10.1002/humu.1380110142;
RA   Susic S., Ahier J., Cole W.G.;
RT   "Pseudoachondroplasia due to the substitution of the highly conserved
RT   Asp482 by Gly in the seventh calmodulin-like repeat of cartilage oligomeric
RT   matrix protein.";
RL   Hum. Mutat. Suppl. 1:S125-S127(1998).
RN   [27]
RP   VARIANT PSACH ARG-348.
RX   PubMed=11746045; DOI=10.1002/ajmg.10062;
RA   Unger S., Koerkkoe J., Krakow D., Lachman R.S., Rimoin D.L., Cohn D.H.;
RT   "Double heterozygosity for pseudoachondroplasia and spondyloepiphyseal
RT   dysplasia congenita.";
RL   Am. J. Med. Genet. 104:140-146(2001).
RN   [28]
RP   VARIANT PSACH ASP-719.
RX   PubMed=11746044; DOI=10.1002/ajmg.10067;
RA   Mabuchi A., Haga N., Ikeda T., Manabe N., Ohashi H., Takatori Y.,
RA   Nakamura K., Ikegawa S.;
RT   "Novel mutation in exon 18 of the cartilage oligomeric matrix protein gene
RT   causes a severe pseudoachondroplasia.";
RL   Am. J. Med. Genet. 104:135-139(2001).
RN   [29]
RP   VARIANTS EDM1 ARG-276; ALA-420 AND MET-585.
RX   PubMed=11565064; DOI=10.1086/324023;
RA   Czarny-Ratajczak M., Lohiniva J., Rogala P., Kozlowski K., Peraelae M.,
RA   Carter L., Spector T.D., Kolodziej L., Seppaenen U., Glazar R.,
RA   Krolewski J., Latos-Bielenska A., Ala-Kokko L.;
RT   "A mutation in COL9A1 causes multiple epiphyseal dysplasia: further
RT   evidence for locus heterogeneity.";
RL   Am. J. Hum. Genet. 69:969-980(2001).
RN   [30]
RP   VARIANTS PSACH SER-234; GLY-290; ARG-299; TYR-326; 341-GLU-ASP-342 DEL;
RP   350-ASN--ASP-372 DEL; VAL-378; ARG-387; 402-GLY--GLY-404 DELINS VAL-CYS;
RP   ARG-440; ASN-446; SER-448; ASP-473 DEL; HIS-473; ASN-475; GLY-482; GLY-507;
RP   GLY-511; GLY-515; ILE-529; ARG-585 AND SER-719, VARIANTS EDM1 GLU-167;
RP   ARG-276; LEU-298; ASP-311; GLY-317; GLY-326; PHE-348; SER-371; TYR-371;
RP   ASN-374; ASN-376; ASN-385; ASP-385 DEL; TYR-385; HIS-397; ARG-404; TYR-410;
RP   LYS-415; GLU-427; 430-CYS--SER-432 DELINS LEU-TRP-CYS; GLU-457 DEL; ASP-473
RP   INS; ASP-501; LYS-523; MET-585; PRO-718 AND TRP-718, AND VARIANT ARG-756.
RX   PubMed=21922596; DOI=10.1002/humu.21611;
RA   Jackson G.C., Mittaz-Crettol L., Taylor J.A., Mortier G.R., Spranger J.,
RA   Zabel B., Le Merrer M., Cormier-Daire V., Hall C.M., Offiah A.,
RA   Wright M.J., Savarirayan R., Nishimura G., Ramsden S.C., Elles R.,
RA   Bonafe L., Superti-Furga A., Unger S., Zankl A., Briggs M.D.;
RT   "Pseudoachondroplasia and multiple epiphyseal dysplasia: A 7-year
RT   comprehensive analysis of the known disease genes identify novel and
RT   recurrent mutations and provides an accurate assessment of their relative
RT   contribution.";
RL   Hum. Mutat. 33:144-157(2012).
RN   [31]
RP   VARIANTS CTS2 GLU-66 AND TRP-718, CHARACTERIZATION OF VARIANTS CTS2 GLU-66
RP   AND TRP-718, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=32686688; DOI=10.1038/s41467-020-17378-z;
RA   Li C., Wang N., Schaeffer A.A., Liu X., Zhao Z., Elliott G., Garrett L.,
RA   Choi N.T., Wang Y., Wang Y., Wang C., Wang J., Chan D., Su P., Cui S.,
RA   Yang Y., Gao B.;
RT   "Mutations in COMP cause familial carpal tunnel syndrome.";
RL   Nat. Commun. 11:3642-3642(2020).
RN   [32]
RP   ERRATUM OF PUBMED:32686688.
RX   PubMed=32747625; DOI=10.1038/s41467-020-17845-7;
RA   Li C., Wang N., Schaeffer A.A., Liu X., Zhao Z., Elliott G., Garrett L.,
RA   Choi N.T., Wang Y., Wang Y., Wang C., Wang J., Chan D., Su P., Cui S.,
RA   Yang Y., Gao B.;
RT   "Author Correction: Mutations in COMP cause familial carpal tunnel
RT   syndrome.";
RL   Nat. Commun. 11:3931-3931(2020).
CC   -!- FUNCTION: Plays a role in the structural integrity of cartilage via its
CC       interaction with other extracellular matrix proteins such as the
CC       collagens and fibronectin. Can mediate the interaction of chondrocytes
CC       with the cartilage extracellular matrix through interaction with cell
CC       surface integrin receptors (PubMed:16051604, PubMed:16542502). Could
CC       play a role in the pathogenesis of osteoarthritis (PubMed:16542502).
CC       Potent suppressor of apoptosis in both primary chondrocytes and
CC       transformed cells. Suppresses apoptosis by blocking the activation of
CC       caspase-3 and by inducing the IAP family of survival proteins (BIRC3,
CC       BIRC2, BIRC5 and XIAP) (PubMed:17993464). Essential for maintaining a
CC       vascular smooth muscle cells (VSMCs) contractile/differentiated
CC       phenotype under physiological and pathological stimuli. Maintains this
CC       phenotype of VSMCs by interacting with ITGA7 (By similarity).
CC       {ECO:0000250|UniProtKB:P35444, ECO:0000269|PubMed:16051604,
CC       ECO:0000269|PubMed:16542502, ECO:0000269|PubMed:17993464}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:10852928, ECO:0000269|PubMed:11084047,
CC         ECO:0000269|PubMed:19276170};
CC       Note=Binds 11-14 calcium ions per subunit.
CC       {ECO:0000269|PubMed:19276170};
CC   -!- SUBUNIT: Pentamer; disulfide-linked (PubMed:32686688). Exists in a more
CC       compact conformation in the presence of calcium and shows a more
CC       extended conformation in the absence of calcium (PubMed:19276170).
CC       Interacts with ITGB3, ITGA5 and FN1. Binding to FN1 requires the
CC       presence of divalent cations (Ca(2+), Mg(2+) or Mn(2+)). The greatest
CC       amount of binding is seen in the presence of Mn(2+) (PubMed:12225811,
CC       PubMed:16051604). Interacts with MATN1, MATN3, MATN4 and ACAN
CC       (PubMed:15075323, PubMed:17588949). Binds heparin, heparan sulfate and
CC       chondroitin sulfate. EDTA dimishes significantly its binding to ACAN
CC       and abolishes its binding to MATN3, MATN4 and chondroitin sulfate
CC       (PubMed:17588949). Interacts with collagen I, II and IX, and
CC       interaction with these collagens is dependent on the presence of zinc
CC       ions (PubMed:11084047). Interacts with ADAMTS12 (PubMed:16611630).
CC       Interacts with ITGA7 (By similarity). {ECO:0000250|UniProtKB:P35444,
CC       ECO:0000269|PubMed:11084047, ECO:0000269|PubMed:12225811,
CC       ECO:0000269|PubMed:15075323, ECO:0000269|PubMed:16051604,
CC       ECO:0000269|PubMed:16611630, ECO:0000269|PubMed:17588949,
CC       ECO:0000269|PubMed:19276170, ECO:0000269|PubMed:32686688}.
CC   -!- INTERACTION:
CC       P49747; P58397: ADAMTS12; NbExp=3; IntAct=EBI-2531022, EBI-9028051;
CC       P49747; P29972: AQP1; NbExp=3; IntAct=EBI-2531022, EBI-745213;
CC       P49747; O00244: ATOX1; NbExp=3; IntAct=EBI-2531022, EBI-10179267;
CC       P49747; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-2531022, EBI-3867333;
CC       P49747; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-2531022, EBI-16439278;
CC       P49747; Q7Z417: NUFIP2; NbExp=3; IntAct=EBI-2531022, EBI-1210753;
CC       P49747; P32242: OTX1; NbExp=7; IntAct=EBI-2531022, EBI-740446;
CC       P49747; Q96EQ0: SGTB; NbExp=3; IntAct=EBI-2531022, EBI-744081;
CC       P49747; P13608: ACAN; Xeno; NbExp=2; IntAct=EBI-2531022, EBI-6259246;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000269|PubMed:32686688}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P49747-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P49747-2; Sequence=VSP_055758;
CC   -!- TISSUE SPECIFICITY: Abundantly expressed in the chondrocyte
CC       extracellular matrix, and is also found in bone, tendon, ligament and
CC       synovium and blood vessels. Increased amounts are produced during late
CC       stages of osteoarthritis in the area adjacent to the main defect.
CC       {ECO:0000269|PubMed:16542502, ECO:0000269|PubMed:32686688}.
CC   -!- DEVELOPMENTAL STAGE: Present during the earliest stages of limb
CC       maturation and is later found in regions where the joints develop.
CC       {ECO:0000269|PubMed:16542502}.
CC   -!- DOMAIN: The cell attachment motif mediates the attachment to
CC       chondrocytes. It mediates the induction of both the IAP family of
CC       survival proteins and the antiapoptotic response.
CC       {ECO:0000269|PubMed:17993464}.
CC   -!- DOMAIN: The TSP C-terminal domain mediates interaction with FN1 and
CC       ACAN. {ECO:0000269|PubMed:17993464}.
CC   -!- DOMAIN: Each of the eight TSP type-3 repeats binds two calcium ions.
CC       The TSP C-terminal domain binds three calcium ions.
CC       {ECO:0000269|PubMed:17993464}.
CC   -!- PTM: Proteolytically cleaved by metalloproteases ADAMTS4 and ADAMTS1
CC       with ADAMTS4 showing more potent activity.
CC       {ECO:0000269|PubMed:39672391}.
CC   -!- DISEASE: Multiple epiphyseal dysplasia 1 (EDM1) [MIM:132400]: A
CC       generalized skeletal dysplasia associated with significant morbidity.
CC       Joint pain, joint deformity, waddling gait, and short stature are the
CC       main clinical signs and symptoms. Radiological examination of the
CC       skeleton shows delayed, irregular mineralization of the epiphyseal
CC       ossification centers and of the centers of the carpal and tarsal bones.
CC       Multiple epiphyseal dysplasia is broadly categorized into the more
CC       severe Fairbank and the milder Ribbing types. The Fairbank type is
CC       characterized by shortness of stature, short and stubby fingers, small
CC       epiphyses in several joints, including the knee, ankle, hand, and hip.
CC       The Ribbing type is confined predominantly to the hip joints and is
CC       characterized by hands that are normal and stature that is normal or
CC       near-normal. {ECO:0000269|PubMed:11084047, ECO:0000269|PubMed:11565064,
CC       ECO:0000269|PubMed:21922596, ECO:0000269|PubMed:7670472,
CC       ECO:0000269|PubMed:9021009, ECO:0000269|PubMed:9184241,
CC       ECO:0000269|PubMed:9452026, ECO:0000269|PubMed:9463320,
CC       ECO:0000269|PubMed:9921895}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Pseudoachondroplasia (PSACH) [MIM:177170]: A skeletal
CC       dysplasia usually manifesting in the second year of life and
CC       characterized by moderate to severe disproportionate short stature,
CC       deformity of the lower limbs, brachydactyly, ligamentous laxity, and
CC       degenerative joint disease. {ECO:0000269|PubMed:10852928,
CC       ECO:0000269|PubMed:11084047, ECO:0000269|PubMed:11746044,
CC       ECO:0000269|PubMed:11746045, ECO:0000269|PubMed:21922596,
CC       ECO:0000269|PubMed:7670471, ECO:0000269|PubMed:7670472,
CC       ECO:0000269|PubMed:9184241, ECO:0000269|PubMed:9452026,
CC       ECO:0000269|PubMed:9452063, ECO:0000269|PubMed:9463320,
CC       ECO:0000269|PubMed:9921895}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Carpal tunnel syndrome 2 (CTS2) [MIM:619161]: An autosomal
CC       dominant form of carpal tunnel syndrome, a condition characterized by
CC       entrapment of the median nerve within the carpal tunnel. Symptoms
CC       include burning pain and paresthesias involving the ventral surface of
CC       the hand and fingers which may radiate proximally. Impairment of
CC       sensation in the distribution of the median nerve and thenar muscle
CC       atrophy may occur. This condition may be associated with repetitive
CC       occupational trauma, wrist injuries, amyloid neuropathies, rheumatoid
CC       arthritis. {ECO:0000269|PubMed:32686688}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the thrombospondin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB86501.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L32137; AAA57253.1; -; mRNA.
DR   EMBL; AB086984; BAC53888.1; -; mRNA.
DR   EMBL; AK296586; BAG59205.1; -; mRNA.
DR   EMBL; AC003107; AAB86501.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471106; EAW84737.1; -; Genomic_DNA.
DR   EMBL; BC110847; AAI10848.1; -; mRNA.
DR   EMBL; BC125092; AAI25093.1; -; mRNA.
DR   EMBL; S79499; AAB35269.1; -; Genomic_DNA.
DR   EMBL; S79500; AAB35270.1; -; Genomic_DNA.
DR   CCDS; CCDS12385.1; -. [P49747-1]
DR   RefSeq; NP_000086.2; NM_000095.2. [P49747-1]
DR   PDB; 3FBY; X-ray; 3.15 A; A/B/C=225-757.
DR   PDBsum; 3FBY; -.
DR   AlphaFoldDB; P49747; -.
DR   SMR; P49747; -.
DR   BioGRID; 107706; 14.
DR   ComplexPortal; CPX-1791; Thrombospondin 5 complex.
DR   FunCoup; P49747; 662.
DR   IntAct; P49747; 21.
DR   STRING; 9606.ENSP00000222271; -.
DR   DrugBank; DB01373; Calcium.
DR   GlyConnect; 1076; 7 N-Linked glycans (2 sites).
DR   GlyCosmos; P49747; 2 sites, 8 glycans.
DR   GlyGen; P49747; 3 sites, 18 N-linked glycans (2 sites), 1 O-linked glycan (1 site).
DR   iPTMnet; P49747; -.
DR   PhosphoSitePlus; P49747; -.
DR   BioMuta; COMP; -.
DR   DMDM; 209572601; -.
DR   jPOST; P49747; -.
DR   MassIVE; P49747; -.
DR   PaxDb; 9606-ENSP00000222271; -.
DR   PeptideAtlas; P49747; -.
DR   ProteomicsDB; 4464; -.
DR   ProteomicsDB; 56060; -. [P49747-1]
DR   Antibodypedia; 15160; 392 antibodies from 30 providers.
DR   DNASU; 1311; -.
DR   Ensembl; ENST00000222271.7; ENSP00000222271.2; ENSG00000105664.11. [P49747-1]
DR   Ensembl; ENST00000425807.1; ENSP00000403792.1; ENSG00000105664.11. [P49747-2]
DR   GeneID; 1311; -.
DR   KEGG; hsa:1311; -.
DR   MANE-Select; ENST00000222271.7; ENSP00000222271.2; NM_000095.3; NP_000086.2.
DR   UCSC; uc002nke.4; human. [P49747-1]
DR   AGR; HGNC:2227; -.
DR   CTD; 1311; -.
DR   DisGeNET; 1311; -.
DR   GeneCards; COMP; -.
DR   GeneReviews; COMP; -.
DR   HGNC; HGNC:2227; COMP.
DR   HPA; ENSG00000105664; Tissue enhanced (adipose tissue, heart muscle, skin).
DR   MalaCards; COMP; -.
DR   MIM; 132400; phenotype.
DR   MIM; 177170; phenotype.
DR   MIM; 600310; gene.
DR   MIM; 619161; phenotype.
DR   neXtProt; NX_P49747; -.
DR   OpenTargets; ENSG00000105664; -.
DR   Orphanet; 93308; Multiple epiphyseal dysplasia type 1.
DR   Orphanet; 750; Pseudoachondroplasia.
DR   PharmGKB; PA26744; -.
DR   VEuPathDB; HostDB:ENSG00000105664; -.
DR   eggNOG; ENOG502QRK8; Eukaryota.
DR   GeneTree; ENSGT00940000162169; -.
DR   InParanoid; P49747; -.
DR   OMA; DSCPFIS; -.
DR   OrthoDB; 14563at2759; -.
DR   PAN-GO; P49747; 1 GO annotation based on evolutionary models.
DR   PhylomeDB; P49747; -.
DR   TreeFam; TF324917; -.
DR   PathwayCommons; P49747; -.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   SignaLink; P49747; -.
DR   BioGRID-ORCS; 1311; 12 hits in 1142 CRISPR screens.
DR   ChiTaRS; COMP; human.
DR   EvolutionaryTrace; P49747; -.
DR   GeneWiki; Cartilage_oligomeric_matrix_protein; -.
DR   GenomeRNAi; 1311; -.
DR   Pharos; P49747; Tbio.
DR   PRO; PR:P49747; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P49747; protein.
DR   Bgee; ENSG00000105664; Expressed in tibia and 136 other cell types or tissues.
DR   ExpressionAtlas; P49747; baseline and differential.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; HDA:BHF-UCL.
DR   GO; GO:0032991; C:protein-containing complex; IEA:Ensembl.
DR   GO; GO:0036122; F:BMP binding; IEA:Ensembl.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0005518; F:collagen binding; IDA:UniProtKB.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; TAS:ProtInc.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; IEA:Ensembl.
DR   GO; GO:0002020; F:protease binding; IPI:BHF-UCL.
DR   GO; GO:0043394; F:proteoglycan binding; IDA:MGI.
DR   GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0048844; P:artery morphogenesis; IEA:Ensembl.
DR   GO; GO:0030509; P:BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0030282; P:bone mineralization; IEA:Ensembl.
DR   GO; GO:1990079; P:cartilage homeostasis; IDA:UniProtKB.
DR   GO; GO:0090398; P:cellular senescence; IEA:Ensembl.
DR   GO; GO:0002063; P:chondrocyte development; IEA:Ensembl.
DR   GO; GO:0035988; P:chondrocyte proliferation; IEA:Ensembl.
DR   GO; GO:0030199; P:collagen fibril organization; IEA:Ensembl.
DR   GO; GO:0003417; P:growth plate cartilage development; IEA:Ensembl.
DR   GO; GO:0060173; P:limb development; IDA:UniProtKB.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0050881; P:musculoskeletal movement; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:1900047; P:negative regulation of hemostasis; IEA:Ensembl.
DR   GO; GO:0070527; P:platelet aggregation; IEA:Ensembl.
DR   GO; GO:1902732; P:positive regulation of chondrocyte proliferation; IEA:Ensembl.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0016485; P:protein processing; IEA:Ensembl.
DR   GO; GO:0009306; P:protein secretion; IEA:Ensembl.
DR   GO; GO:0030500; P:regulation of bone mineralization; IEA:Ensembl.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0006986; P:response to unfolded protein; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   GO; GO:0043588; P:skin development; IEA:Ensembl.
DR   GO; GO:0035989; P:tendon development; IEA:Ensembl.
DR   GO; GO:0097084; P:vascular associated smooth muscle cell development; IEA:Ensembl.
DR   GO; GO:0014829; P:vascular associated smooth muscle contraction; IEA:Ensembl.
DR   CDD; cd00054; EGF_CA; 2.
DR   CDD; cd16077; TSP-5cc; 1.
DR   FunFam; 2.10.25.10:FF:000346; Cartilage oligomeric matrix protein; 1.
DR   FunFam; 4.10.1080.10:FF:000004; Cartilage oligomeric matrix protein; 1.
DR   FunFam; 2.10.25.10:FF:000025; Thrombospondin 3; 1.
DR   FunFam; 2.10.25.10:FF:000027; Thrombospondin 3; 1.
DR   FunFam; 2.60.120.200:FF:000002; Thrombospondin 3; 1.
DR   FunFam; 4.10.1080.10:FF:000001; Thrombospondin 3; 1.
DR   FunFam; 2.10.25.10:FF:000170; thrombospondin-3 isoform X1; 1.
DR   FunFam; 1.20.5.10:FF:000001; thrombospondin-3 isoform X2; 1.
DR   Gene3D; 1.20.5.10; -; 1.
DR   Gene3D; 2.60.120.200; -; 1.
DR   Gene3D; 2.10.25.10; Laminin; 4.
DR   Gene3D; 4.10.1080.10; TSP type-3 repeat; 2.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR049883; NOTCH1_EGF-like.
DR   InterPro; IPR003367; Thrombospondin_3-like_rpt.
DR   InterPro; IPR017897; Thrombospondin_3_rpt.
DR   InterPro; IPR008859; Thrombospondin_C.
DR   InterPro; IPR039081; TSP-5_cc.
DR   InterPro; IPR024665; TSP/COMP_coiled-coil.
DR   InterPro; IPR046970; TSP/COMP_coiled-coil_sf.
DR   InterPro; IPR028974; TSP_type-3_rpt.
DR   PANTHER; PTHR10199:SF88; CARTILAGE OLIGOMERIC MATRIX PROTEIN; 1.
DR   PANTHER; PTHR10199; THROMBOSPONDIN; 1.
DR   Pfam; PF11598; COMP; 1.
DR   Pfam; PF07645; EGF_CA; 2.
DR   Pfam; PF02412; TSP_3; 5.
DR   Pfam; PF05735; TSP_C; 1.
DR   SMART; SM00181; EGF; 4.
DR   SMART; SM00179; EGF_CA; 3.
DR   SUPFAM; SSF58006; Assembly domain of cartilage oligomeric matrix protein; 1.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 1.
DR   SUPFAM; SSF57196; EGF/Laminin; 1.
DR   SUPFAM; SSF57184; Growth factor receptor domain; 1.
DR   SUPFAM; SSF103647; TSP type-3 repeat; 3.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 3.
DR   PROSITE; PS01187; EGF_CA; 2.
DR   PROSITE; PS51234; TSP3; 8.
DR   PROSITE; PS51236; TSP_CTER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Calcium; Cell adhesion;
KW   Direct protein sequencing; Disease variant; Disulfide bond; Dwarfism;
KW   EGF-like domain; Extracellular matrix; Glycoprotein; Heparin-binding;
KW   Proteomics identification; Reference proteome; Repeat; Secreted; Signal.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000255"
FT   CHAIN           21..757
FT                   /note="Cartilage oligomeric matrix protein"
FT                   /id="PRO_0000035857"
FT   DOMAIN          87..126
FT                   /note="EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          127..179
FT                   /note="EGF-like 2; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          180..222
FT                   /note="EGF-like 3; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          225..267
FT                   /note="EGF-like 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   REPEAT          268..300
FT                   /note="TSP type-3 1"
FT   REPEAT          301..336
FT                   /note="TSP type-3 2"
FT   REPEAT          337..359
FT                   /note="TSP type-3 3"
FT   REPEAT          360..395
FT                   /note="TSP type-3 4"
FT   REPEAT          396..418
FT                   /note="TSP type-3 5"
FT   REPEAT          419..456
FT                   /note="TSP type-3 6"
FT   REPEAT          457..492
FT                   /note="TSP type-3 7"
FT   REPEAT          493..528
FT                   /note="TSP type-3 8"
FT   DOMAIN          532..746
FT                   /note="TSP C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00635"
FT   REGION          22..86
FT                   /note="COMP N-terminal"
FT   REGION          298..503
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          527..757
FT                   /note="Mediates cell survival and induction of the IAP
FT                   family of survival proteins"
FT   MOTIF           367..369
FT                   /note="Cell attachment site"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        334..346
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        352..370
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        467..476
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            77..78
FT                   /note="Cleavage; by ADAMTS4"
FT   CARBOHYD        121
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        742
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19276170"
FT   DISULFID        69
FT                   /note="Interchain"
FT                   /evidence="ECO:0000305|PubMed:19276170"
FT   DISULFID        72
FT                   /note="Interchain"
FT                   /evidence="ECO:0000305|PubMed:19276170"
FT   DISULFID        91..102
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        96..111
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        114..125
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        131..142
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        136..151
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        154..178
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        184..197
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        191..206
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        209..221
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        229..243
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:19276170"
FT   DISULFID        237..253
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:19276170"
FT   DISULFID        255..266
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:19276170"
FT   DISULFID        282..287
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:19276170"
FT   DISULFID        292..312
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:19276170"
FT   DISULFID        328..348
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:19276170"
FT   DISULFID        351..371
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:19276170"
FT   DISULFID        387..407
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:19276170"
FT   DISULFID        410..430
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:19276170"
FT   DISULFID        448..468
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:19276170"
FT   DISULFID        484..504
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:19276170"
FT   DISULFID        520..741
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:19276170"
FT   VAR_SEQ         129..181
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055758"
FT   VARIANT         50
FT                   /note="E -> D"
FT                   /evidence="ECO:0000269|PubMed:7713493, ECO:0000269|Ref.2"
FT                   /id="VAR_016254"
FT   VARIANT         51
FT                   /note="L -> W"
FT                   /evidence="ECO:0000269|PubMed:7713493, ECO:0000269|Ref.2"
FT                   /id="VAR_016255"
FT   VARIANT         66
FT                   /note="V -> E (in CTS2; reduced secretion in tendon cells;
FT                   no effect on secretion in chondrocytes; disrupted
FT                   pentamerization; induced ER stress; dbSNP:rs2055205599)"
FT                   /evidence="ECO:0000269|PubMed:32686688"
FT                   /id="VAR_085230"
FT   VARIANT         109
FT                   /note="A -> G"
FT                   /evidence="ECO:0000269|PubMed:7713493, ECO:0000269|Ref.2"
FT                   /id="VAR_016257"
FT   VARIANT         167
FT                   /note="G -> E (in EDM1; dbSNP:rs763887855)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066789"
FT   VARIANT         224
FT                   /note="R -> G"
FT                   /evidence="ECO:0000269|PubMed:7713493, ECO:0000269|Ref.2"
FT                   /id="VAR_016258"
FT   VARIANT         234
FT                   /note="P -> S (in PSACH; dbSNP:rs557483957)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066790"
FT   VARIANT         276
FT                   /note="P -> R (in EDM1; dbSNP:rs1311845746)"
FT                   /evidence="ECO:0000269|PubMed:11565064,
FT                   ECO:0000269|PubMed:21922596"
FT                   /id="VAR_026239"
FT   VARIANT         285
FT                   /note="R -> P"
FT                   /evidence="ECO:0000269|PubMed:7713493, ECO:0000269|Ref.2"
FT                   /id="VAR_016261"
FT   VARIANT         290
FT                   /note="D -> G (in PSACH; dbSNP:rs1568556118)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066791"
FT   VARIANT         290
FT                   /note="D -> N (in PSACH; mild form)"
FT                   /evidence="ECO:0000269|PubMed:9921895"
FT                   /id="VAR_007614"
FT   VARIANT         298
FT                   /note="S -> L (in EDM1; phenotypic features overlapping
FT                   with mild PSACH)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066792"
FT   VARIANT         299
FT                   /note="G -> R (in PSACH; dbSNP:rs2145903238)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_007615"
FT   VARIANT         311
FT                   /note="A -> D (in EDM1)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066793"
FT   VARIANT         317
FT                   /note="D -> G (in EDM1; atypical form)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066794"
FT   VARIANT         326
FT                   /note="D -> G (in EDM1)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066795"
FT   VARIANT         326
FT                   /note="D -> Y (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066796"
FT   VARIANT         328
FT                   /note="C -> R (in PSACH; mild form; dbSNP:rs137852653)"
FT                   /evidence="ECO:0000269|PubMed:7670472,
FT                   ECO:0000269|PubMed:9452026"
FT                   /id="VAR_007616"
FT   VARIANT         341..342
FT                   /note="Missing (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066797"
FT   VARIANT         342
FT                   /note="D -> Y (in EDM1; Fairbank type; dbSNP:rs137852652)"
FT                   /evidence="ECO:0000269|PubMed:7670472,
FT                   ECO:0000269|PubMed:9452026"
FT                   /id="VAR_007617"
FT   VARIANT         348
FT                   /note="C -> F (in EDM1)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066798"
FT   VARIANT         348
FT                   /note="C -> R (in PSACH; dbSNP:rs137852656)"
FT                   /evidence="ECO:0000269|PubMed:11746045"
FT                   /id="VAR_017102"
FT   VARIANT         349
FT                   /note="D -> V (in PSACH; mild form)"
FT                   /evidence="ECO:0000269|PubMed:9921895"
FT                   /id="VAR_007618"
FT   VARIANT         350..372
FT                   /note="Missing (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066799"
FT   VARIANT         361
FT                   /note="D -> V (in EDM1; Fairbank type)"
FT                   /evidence="ECO:0000269|PubMed:9921895"
FT                   /id="VAR_007619"
FT   VARIANT         361
FT                   /note="D -> Y (in EDM1; binds less calcium)"
FT                   /evidence="ECO:0000269|PubMed:11084047,
FT                   ECO:0000269|PubMed:9452026"
FT                   /id="VAR_007620"
FT   VARIANT         367..368
FT                   /note="Missing (in EDM1)"
FT                   /evidence="ECO:0000269|PubMed:9452026"
FT                   /id="VAR_007621"
FT   VARIANT         371
FT                   /note="C -> S (in EDM1; Fairbank type)"
FT                   /evidence="ECO:0000269|PubMed:21922596,
FT                   ECO:0000269|PubMed:9184241"
FT                   /id="VAR_007622"
FT   VARIANT         371
FT                   /note="C -> Y (in EDM1; dbSNP:rs1057521130)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066800"
FT   VARIANT         372
FT                   /note="Missing (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:9452026"
FT                   /id="VAR_007623"
FT   VARIANT         374
FT                   /note="D -> N (in EDM1)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066801"
FT   VARIANT         374
FT                   /note="Missing (in PSACH; mild form)"
FT                   /id="VAR_007624"
FT   VARIANT         376
FT                   /note="D -> N (in EDM1; dbSNP:rs1555791556)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066802"
FT   VARIANT         378
FT                   /note="D -> V (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066803"
FT   VARIANT         381
FT                   /note="R -> C (in dbSNP:rs3179763)"
FT                   /id="VAR_046796"
FT   VARIANT         385
FT                   /note="D -> N (in EDM1; atypical form; dbSNP:rs1601054715)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066804"
FT   VARIANT         385
FT                   /note="D -> Y (in EDM1; atypical form; dbSNP:rs1601054715)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066805"
FT   VARIANT         385
FT                   /note="Missing (in EDM1; dbSNP:rs2145901379)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066806"
FT   VARIANT         387
FT                   /note="C -> G (in PSACH; mild form)"
FT                   /evidence="ECO:0000269|PubMed:9921895"
FT                   /id="VAR_007625"
FT   VARIANT         387
FT                   /note="C -> R (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066807"
FT   VARIANT         391..394
FT                   /note="PNSD -> V (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:9452026"
FT                   /id="VAR_007626"
FT   VARIANT         397
FT                   /note="D -> H (in EDM1; dbSNP:rs1479804676)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066808"
FT   VARIANT         402..404
FT                   /note="GIG -> VC (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066809"
FT   VARIANT         404
FT                   /note="G -> R (in EDM1; dbSNP:rs2055168912)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066810"
FT   VARIANT         408
FT                   /note="D -> Y (in EDM1)"
FT                   /evidence="ECO:0000269|PubMed:9452026"
FT                   /id="VAR_007627"
FT   VARIANT         410
FT                   /note="C -> Y (in EDM1; phenotype overlapping with mild
FT                   PSACH; dbSNP:rs2145901300)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066811"
FT   VARIANT         415
FT                   /note="N -> K (in EDM1)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066812"
FT   VARIANT         420
FT                   /note="D -> A (in EDM1)"
FT                   /evidence="ECO:0000269|PubMed:11565064"
FT                   /id="VAR_026240"
FT   VARIANT         427
FT                   /note="G -> E (in EDM1; dbSNP:rs2145901034)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066813"
FT   VARIANT         430..432
FT                   /note="CDS -> LWC (in EDM1)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066814"
FT   VARIANT         440
FT                   /note="G -> E (in PSACH; mild form; dbSNP:rs2145900919)"
FT                   /evidence="ECO:0000269|PubMed:9463320"
FT                   /id="VAR_007628"
FT   VARIANT         440
FT                   /note="G -> R (in PSACH; dbSNP:rs1601053997)"
FT                   /evidence="ECO:0000269|PubMed:21922596,
FT                   ECO:0000269|PubMed:9452026"
FT                   /id="VAR_007629"
FT   VARIANT         446
FT                   /note="D -> N (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066815"
FT   VARIANT         448
FT                   /note="C -> S (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066816"
FT   VARIANT         453
FT                   /note="N -> S (in EDM1; Fairbank type; dbSNP:rs28936668)"
FT                   /evidence="ECO:0000269|PubMed:9463320"
FT                   /id="VAR_007630"
FT   VARIANT         457
FT                   /note="Missing (in EDM1)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066817"
FT   VARIANT         459
FT                   /note="Missing (in PSACH; severe form; dbSNP:rs2145900868)"
FT                   /evidence="ECO:0000269|PubMed:7670471,
FT                   ECO:0000269|PubMed:9452026"
FT                   /id="VAR_007631"
FT   VARIANT         468
FT                   /note="C -> Y (in PSACH; severe form; dbSNP:rs137852651)"
FT                   /evidence="ECO:0000269|PubMed:7670471,
FT                   ECO:0000269|PubMed:9452026"
FT                   /id="VAR_007632"
FT   VARIANT         469
FT                   /note="Missing (in PSACH; severe form; MUT3 mutant; most
FT                   common mutation; binds less calcium and causes misfolding
FT                   of the protein; greatly reduced interaction with ACAN;
FT                   reduced interaction with collagen)"
FT                   /evidence="ECO:0000269|PubMed:10852928,
FT                   ECO:0000269|PubMed:11084047, ECO:0000269|PubMed:9452026"
FT                   /id="VAR_007633"
FT   VARIANT         472
FT                   /note="D -> Y (in PSACH; severe form; dbSNP:rs137852650)"
FT                   /evidence="ECO:0000269|PubMed:7670471,
FT                   ECO:0000269|PubMed:9452026"
FT                   /id="VAR_007634"
FT   VARIANT         473
FT                   /note="D -> DD (in EDM1)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066818"
FT   VARIANT         473
FT                   /note="D -> G (in PSACH; severe form; dbSNP:rs28936669)"
FT                   /evidence="ECO:0000269|PubMed:9921895"
FT                   /id="VAR_007635"
FT   VARIANT         473
FT                   /note="D -> H (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066819"
FT   VARIANT         473
FT                   /note="Missing (in PSACH; severe form; dbSNP:rs193922900)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_007636"
FT   VARIANT         475
FT                   /note="D -> N (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066820"
FT   VARIANT         482
FT                   /note="D -> G (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:21922596,
FT                   ECO:0000269|PubMed:9452063"
FT                   /id="VAR_007637"
FT   VARIANT         501
FT                   /note="G -> D (in EDM1; dbSNP:rs1555791425)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066821"
FT   VARIANT         507
FT                   /note="D -> G (in PSACH; dbSNP:rs2145900497)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066822"
FT   VARIANT         511
FT                   /note="D -> G (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066823"
FT   VARIANT         513..516
FT                   /note="Missing (in PSACH; mild form)"
FT                   /evidence="ECO:0000269|PubMed:9184241"
FT                   /id="VAR_007638"
FT   VARIANT         515
FT                   /note="D -> G (in PSACH)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066824"
FT   VARIANT         518
FT                   /note="D -> N (in PSACH; mild form; dbSNP:rs1359984033)"
FT                   /evidence="ECO:0000269|PubMed:9921895"
FT                   /id="VAR_007639"
FT   VARIANT         523
FT                   /note="N -> K (in EDM1; Ribbing type; dbSNP:rs137852654)"
FT                   /evidence="ECO:0000269|PubMed:21922596,
FT                   ECO:0000269|PubMed:9021009"
FT                   /id="VAR_007640"
FT   VARIANT         529
FT                   /note="T -> I (in PSACH; dbSNP:rs312262903)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066825"
FT   VARIANT         585
FT                   /note="T -> M (in PSACH; mild form and EDM1;
FT                   dbSNP:rs312262900)"
FT                   /evidence="ECO:0000269|PubMed:11565064,
FT                   ECO:0000269|PubMed:21922596"
FT                   /id="VAR_007641"
FT   VARIANT         585
FT                   /note="T -> R (in EDM1 and PSACH; dbSNP:rs312262900)"
FT                   /evidence="ECO:0000269|PubMed:21922596,
FT                   ECO:0000269|PubMed:9463320"
FT                   /id="VAR_007642"
FT   VARIANT         718
FT                   /note="R -> P (in EDM1; dbSNP:rs149551600)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066826"
FT   VARIANT         718
FT                   /note="R -> W (in EDM1 and CTS2; reduced secretion in
FT                   tendon cells and chondrocytes; dbSNP:rs28936368)"
FT                   /evidence="ECO:0000269|PubMed:21922596,
FT                   ECO:0000269|PubMed:32686688"
FT                   /id="VAR_066827"
FT   VARIANT         719
FT                   /note="G -> D (in PSACH; severe; dbSNP:rs137852655)"
FT                   /evidence="ECO:0000269|PubMed:11746044"
FT                   /id="VAR_017103"
FT   VARIANT         719
FT                   /note="G -> S (in PSACH; dbSNP:rs312262904)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066828"
FT   VARIANT         756
FT                   /note="Q -> R (in a patient with multiple epiphyseal
FT                   dysplasia; dbSNP:rs61752496)"
FT                   /evidence="ECO:0000269|PubMed:21922596"
FT                   /id="VAR_066829"
FT   CONFLICT        256
FT                   /note="A -> R (in Ref. 1; AAA57253 and 2; BAC53888)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        340
FT                   /note="D -> Y (in Ref. 7; AAB35270)"
FT                   /evidence="ECO:0000305"
FT   STRAND          232..234
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          241..245
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          251..255
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          259..265
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          272..274
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   HELIX           285..287
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          291..295
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          306..308
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   HELIX           310..312
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   TURN            314..317
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          319..321
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   HELIX           323..325
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          327..331
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          342..344
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   HELIX           346..348
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          364..367
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   HELIX           369..371
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          378..380
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          401..403
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   HELIX           405..407
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          424..426
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   TURN            428..430
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   HELIX           443..445
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          462..464
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   TURN            466..468
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          470..473
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          475..477
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   HELIX           479..481
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          495..500
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   TURN            503..506
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          511..513
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   HELIX           515..517
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          532..540
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          551..553
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   TURN            555..557
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          560..562
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          567..588
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          596..605
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          608..617
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          625..627
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          636..641
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   HELIX           648..655
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          656..658
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   TURN            661..663
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          664..669
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          681..689
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   HELIX           690..692
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          694..701
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          704..708
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          716..728
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   STRAND          732..741
FT                   /evidence="ECO:0007829|PDB:3FBY"
FT   HELIX           748..754
FT                   /evidence="ECO:0007829|PDB:3FBY"
SQ   SEQUENCE   757 AA;  82860 MW;  A0B73AADB39FBC7B CRC64;
     MVPDTACVLL LTLAALGASG QGQSPLGSDL GPQMLRELQE TNAALQDVRE LLRQQVREIT
     FLKNTVMECD ACGMQQSVRT GLPSVRPLLH CAPGFCFPGV ACIQTESGAR CGPCPAGFTG
     NGSHCTDVNE CNAHPCFPRV RCINTSPGFR CEACPPGYSG PTHQGVGLAF AKANKQVCTD
     INECETGQHN CVPNSVCINT RGSFQCGPCQ PGFVGDQASG CQRRAQRFCP DGSPSECHEH
     ADCVLERDGS RSCVCAVGWA GNGILCGRDT DLDGFPDEKL RCPERQCRKD NCVTVPNSGQ
     EDVDRDGIGD ACDPDADGDG VPNEKDNCPL VRNPDQRNTD EDKWGDACDN CRSQKNDDQK
     DTDQDGRGDA CDDDIDGDRI RNQADNCPRV PNSDQKDSDG DGIGDACDNC PQKSNPDQAD
     VDHDFVGDAC DSDQDQDGDG HQDSRDNCPT VPNSAQEDSD HDGQGDACDD DDDNDGVPDS
     RDNCRLVPNP GQEDADRDGV GDVCQDDFDA DKVVDKIDVC PENAEVTLTD FRAFQTVVLD
     PEGDAQIDPN WVVLNQGREI VQTMNSDPGL AVGYTAFNGV DFEGTFHVNT VTDDDYAGFI
     FGYQDSSSFY VVMWKQMEQT YWQANPFRAV AEPGIQLKAV KSSTGPGEQL RNALWHTGDT
     ESQVRLLWKD PRNVGWKDKK SYRWFLQHRP QVGYIRVRFY EGPELVADSN VVLDTTMRGG
     RLGVFCFSQE NIIWANLRYR CNDTIPEDYE THQLRQA
//
